Search
DL-dimyristoylphosphatidylglycerol
go.drugbank.com/drugs/DB11284ApprovedDL-dimyristoylphosphatidylglycerol is a phospholipid used in commercially available pharmaceutical preparations to solubilize drugs for injection.
Sevabertinib
go.drugbank.com/drugs/DB21667ApprovedInvestigationalSevabertinib is a kinase inhibitor indicated for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain … [L54638] It was granted accelerated approval by the FDA on November 19th, 2025.[L54608]
Umeclidinium
go.drugbank.com/drugs/DB09076ApprovedInvestigationalCOPD is a progressive obstructive lung disease characterized by shortness of breath, cough, sputum production, and chronically poor airflow with a forced expiratory volume in 1 second (FEV1) of less than … [A7718,A7714] Umeclidinium was approved by the FDA in April 2014 under the brand name Incruse Ellipta as a standalone product.
Eflapegrastim
go.drugbank.com/drugs/DB15001ApprovedInvestigationalin which the patient develops an infection during a period of significant neutropenia. … [L43135] In September 2022, eflapegrastim was approved by the US FDA as a prophylactic against infection, as manifested by febrile neutropenia, in patients receiving certain myelosuppressive anti-cancer
Tafasitamab
go.drugbank.com/drugs/DB15044ApprovedInvestigational[L15292,A191829] The CD19 surface protein is highly expressed on the surface of B-cells, where it appears to play a role in enhancing B-cell receptor signaling. … leukemia (CLL), small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL))[L15302] has made it a desirable target in the treatment these B-cell malignancies.
Romidepsin
go.drugbank.com/drugs/DB06176ApprovedInvestigationalRomidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic IndexClobazam
go.drugbank.com/drugs/DB00349ApprovedIllicitInvestigationalClobazam was first synthesized in 1966 and first published in 1969, following the incidental synthesis and discovery of the first benzodiazepine chlordiazepoxide in the 1950s. … [A521,A522] In October 21, 2011, the FDA approved clobazam as an adjunctive treatment for seizures associated with Lennox-Gastaut syndrome in adults and children aged two years and older.
Categories: GABA-A Receptor AgonistsTerbutaline
go.drugbank.com/drugs/DB00871ApprovedInvestigational[A230328] It is a selective beta-2 adrenergic agonist used as a bronchodilator in asthmatic patients.[A230333,L32093,L32098] Terbutaline was granted FDA approval on 25 March 1974.[L32088] … Terbutaline was first synthesized in 1966[A230333] and described in the literature in the late 1960s and early 1970s.
Products: บรองโคนิล (N), TERBUTALIN AL 2.5Fulzerasib
go.drugbank.com/drugs/DB21609Investigational112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation). … Fulzerasib is a small molecule drug. The usage of the INN stem '-rasib' in the name indicates that Fulzerasib is a Ras protein inhibitor.
Mirikizumab
go.drugbank.com/drugs/DB14910ApprovedInvestigational[L46237,L46257] Mirikizumab is approved in Japan[L46252] and received a positive opinion from the EMA's Committee for Medicinal Products for Human Use in March 2023. … Mirikizumab is a monoclonal antibody developed by Eli Lilly intended to treat ulcerative colitis.